Noevir Holdings came into this earnings print with the stock roughly flat over the past week and modestly ahead over the last three months, trading at ¥4,670 and on a P/E below both peers and the wider personal products industry. The headline this quarter is earnings quality rather than top line excitement. Trailing twelve month basic earnings per share sit in the mid ¥200s while net profit margin holds in the low teens, which keeps the story centered on profitability and a generous near 5% dividend that already stretches earnings and free cash flow coverage.
Love Noevir Holdings' steady profitability but unsure about a dividend that already leans heavily on current earnings and cash flow coverage? You may want to explore 50 dividend fortresses for income ideas that offer higher yields with balance sheets designed to better support them over time.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 TTM): ¥63,516 million vs. Q3 2025 TTM ¥62,868 million (stable year on year)
- Net Income (Excl. Extra Items, Q3 2026 TTM): ¥7,996 million vs. Q3 2025 TTM ¥7,603 million (modest improvement)
- Basic EPS (Earnings Per Share, Q3 2026 TTM): ¥234.10 vs. Q3 2025 TTM ¥222.59 (modest improvement)
- Net Profit Margin (Q3 2026 TTM): 12.6% vs. Q3 2025 TTM 12.1% (slight margin expansion)
Prefer clean charts instead of another wall of earnings tables and ratios? See Noevir Holdings’ full financial picture, including a clear view of its dividend track record and coverage, in our company report for Noevir Holdings.
Noevir earnings gently support the defensive story
For investors drawn to Noevir Holdings as a steady consumer and healthcare blend, the latest numbers lean in your favor. Revenue across the trailing twelve months is described as stable and net income and basic EPS both show modest improvement. Net profit margin edges higher to 12.6%. That combination points to a business model that is holding its ground and slowly tightening profitability rather than chasing aggressive expansion. It fits a picture of dependable brands in everyday categories that can support a more income focused role in a portfolio.
Dividend strain keeps Noevir’s risk debate alive
The bear case around Noevir Holdings mostly centers on capital allocation and complexity rather than near term earnings stress. The dividend yield near 5% already leans heavily on current earnings and free cash flow coverage, and that tension has not eased. Profitability is healthy but not widening dramatically, so the payout remains a key pressure point. With revenue and earnings moving only modestly, the latest results do little to resolve concerns about how comfortably the company can fund both a high dividend and any future reinvestment or simplification of non core operations.
Reveal where the calm surface around Noevir Holdings at ¥4,670 might hide a sharper turn in the story and what the street is quietly modeling for revenue, earnings and dividends over the next few years with the full analyst estimates for Noevir Holdings.Stay Ahead With Simply Wall St
If Noevir Holdings’ steady profitability and stretched dividend coverage have caught your eye, register for free with Simply Wall St and add it to your Watchlist to track share price against fair value and watch for a more comfortable entry point. After you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the updates that matter most to your holdings. For longer term conviction, tap into the Community to see how other investors are thinking about risks, catalysts and portfolio fit. This combination helps you surface hidden drivers and potential problem signs early so you can stay ahead of the market.
Curious About Alternatives Beyond Noevir
Some stocks quietly build breakout momentum while others are already flying and getting caught by latecomers. Scan fresh ideas that are under the radar for now and consider them carefully.
- Spot cash rich businesses that could handle shocks more comfortably by reviewing the curated list of solid balance sheet and fundamentals stocks (38 results) before the crowd starts chasing quality.
- Focus on resilient companies where risk scores stay contained and business models look steadier by working through the hand picked 58 resilient stocks with low risk scores while it remains relevant.
- Track where AI earnings momentum is paired with real profits instead of cash burn by scanning the focused list of 68 profitable AI stocks that aren't just burning cash and identifying opportunities early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com